News und Analysen
Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis verstärkt sein CSR-Engagement durch den Beitritt zum United Nations Global Compact und die Anwendung der Norm ISO 26000
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Update on SENS-401
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis veröffentlicht Geschäftsbericht für 2021
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Publishes Its 2021 Annual Report
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Newron Announces 2021 Financial Results and Provides Outlook for 2022
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
DGAP-News: Newron announces 2021 financial results and provides outlook for 2022
DGAP-News: Newron gibt Geschäftsergebnisse 2021 und Ausblick 2022 bekannt
Valbiotis kündigt bevorstehende organisatorische Änderungen im Vorstand an
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Announces Upcoming Organizational Changes of its Board of Directors
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Valbiotis veröffentlicht Finanzkommunikationskalender 2022
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
Valbiotis Presents Its 2022 Financial Communication Calendar
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides an update on clinical results and timelines
Valbiotis gibt Genehmigung für den Start der zwei klinischen Phase-II/III-Studien INSIGHT und INSIGHT 2 bekannt - der letzte Schritt in der Entwicklung von TOTUM•854 zur Senkung von Blutdruck
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive biomarker data from the ongoing
Lysogene Provides Medical Update
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides a medical update.
First
Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Models at the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion to Present New Data on OTOF Gene Therapy at the Association for Research in Otolaryngology ARO 45th Annual MidWinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license
Valbiotis: entscheidende Phase mit Studiendaten für wichtige Indikationen – für 2022 werden Ergebnisse für Prädiabetes, Hypercholesterinämie und Bluthochdruck erwartet
Pflichtmitteilung:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and